This study is testing a drug called efimosfermin in people with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis (scarring of the liver that is stable). You would receive either efimosfermin or a placebo (an inactive substance) through injections under the skin. Researchers want to see if efimosfermin is safe, how well your body handles it, and if it shows early signs of working. They are also looking at how the drug moves through your body. To join, you need to be between 18 and 75 years old, have a history of at least two metabolic syndrome components, and a liver biopsy confirming MASH with F4 fibrosis (the most severe stage of scarring). The main goal is to track any side effects you might experience over about 100 weeks.

Study design

This is an interventional study planning to enroll 42 participants. It compares efimosfermin to a placebo.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for treatment-related side effects for up to 100 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.